Opko Health Inc. (NYSE:OPK) Completes Enrollment for Its Human Growth Hormone (hGH-CTP)


Dallas, Texas 07/13/2015 (Financialstrend) – Opko Health Inc. (NYSE:OPK) has set the stage for a single pivotal Phase 3 trial of its human growth hormone (hGH-CTP) after completing enrollment. The clinical study seeks to evaluate the safety and efficacy of the hormone with a primary endpoint being its superiority compared to Placebo.

 Commercialization Plans

Opko Health Inc. (NYSE:OPK) is to carry out the trial in two treatment periods made of a 26-week double blind placebo controlled period and 26-week open label extension.  The company plans to carry out a regulatory submission upon completion of the study in the second half of 2016.

 Commercialization of the drug upon approval by the FDA should not be a problem as the company already has a worldwide collaboration agreement with Pfizer for the drug.  The company starts the phase 3 study awaiting the FDA decision on Rolapitant, a nausea and vomiting drug whose rights it purchased in 2009.

 Should Rolapitant attain the much-needed FDA approval, then Opko Health Inc. (NYSE:OPK) will be on course to receive up to $121 million in milestone payment, as well as royalty payments from sales. In May, the biopharmaceutical company filed for FDA approval for Rayaldee a prohomorne for vitamin D.

 Vitamin D Deficiency drug

The company hopes to use the drug to vie for the vitamin D deficiency marketplace valued at $12 billion.  Opko Health Inc. (NYSE:OPK) has already initiated plans to hire 20 to 40 sales rep as it remains confident of receiving the FDA approval.  Vitamin D deficiency is a major deficiency facing many people around the world especially those diagnosed with Chronic Kidney disease.

There is no doubt that the stock has a number of catalyst on the horizon that could act as a catalyst going forward. However caution should also be taken as some of the catalysts might already be factored into the stock price already

 Separately Opko Health Inc. (NYSE:OPK) has opted for an early termination of the waiting period for the planned acquisition of Bio-Reference, granted under the HSR improvement act effectively on July 1, 2015.

Subscribe to get your free report!

* indicates required
*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.